medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 3

<< Back Next >>

Gac Med Mex 2017; 153 (3)

Nanodevices that acts as nanocarriers for controlled and directed drug delivery to select cells, organs or tissues in cardiovascular diseases

Vélez-Reséndiz JM, Vélez-Arvízu JJ

Language: English
References: 76
Page: 354-360
PDF size: 99.23 Kb.


ABSTRACT

Cardiovascular disease, which today represents the main cause of death worldwide, is a likely candidate for the application of nanotechnology in the near future. Nanocarriers are currently being developed to deliver medicine (smart drugs) to selected targets in cells and tissues of blood vessels and the heart, as well as to aid in diagnosis and screening for early detection and individualized treatment. Other applications of nanotechnology hold promise for the long run, such as using nanodevices for drug delivery or correcting the misfolding of proteins. With super-potent effects, nanoparticles should be able to evoke therapeutic effects at a lower dose and for longer periods. The development of nanodevices and nanocarriers must take an integral approach that considers many properties—physical, chemical, biological, biochemical, anatomical, morphological, physiological, pharmacological, toxicological, mechanical, electrical, magnetic, thermodynamic, and optical—in order to evaluate biocompatibility and therefore avoid toxicological and/or other adverse effects. Intensified research in relation to nanocarriers and other nanotechnology could help reduce morbidity and mortality in cardiovascular disease.


REFERENCES

  1. Global status report on noncommunicable diseases 2010. Geneve. World Health Organization. Available at: http://www.who.int/nmh/publications/ ncd_report2010/en/

  2. Mathers CD, Loncar D. Protections of global mortality and burden of disease from 2002 at 2030. PLoS Med. 2006;3:e442.

  3. Safari J, Zarnegar Z. Advanced drug delivery systems: Nanotechnology of health design: A review. J Saudi Chem Soc. 2014;18:85-99.

  4. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44:1029-38.

  5. Devaraj S, Munichandraiah N. Effect of crystallographic structure of MnO2 on its electrochemical capacitance properties. J Phys Chem C. 2008;112:4406-17.

  6. Cui H, Wang J. Progress in the development of nanotheranostic systems. Theranostics. 2016;6:915-7.

  7. Karimi M, Bahrami S, Ravari SB, et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13:1609-23.

  8. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-60.

  9. Chow EK, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med. 2013;5:216rv4.

  10. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655-72.

  11. Mitragotri S, Anderson DG, Chen X, et al. Accelerating the translation of nanomaterials in biomedicine. ACS Nano. 2015;9:6644-54.

  12. Zhu G, Zheng J, Song E, et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA. 2013;110:7998-8003.

  13. Lu Y, Sun W, Gu Z. Stimuli-responsive nanomaterials for therapeutic protein delivery. J Control Release. 2014;194:1-19.

  14. Li S, Gaddes ER, Chen N, Wang Y. Molecular encryption and reconfiguration for remodeling of dynamic hydrogels. Angew Chem Int Ed Engl. 2015;54:5957-61.

  15. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62:1064-79.

  16. Zheng J, Zhang C, Dickson RM. Highly fluorescent, water-soluble, size-tunable gold quantum dots. Phys Rev Lett. 2004;93:077402.

  17. Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res. 2011;44:883-92.

  18. Niu G, Chen X. Lymphatic imaging: focus on imaging probes. Theranostics. 2015;5:686-97.

  19. Nomoto T, Fukushima S, Kumagai M, et al. Three-layered polyplex micelle as a multifunctional nanocarrier platform for light-induced systemic gene transfer. Nat Commun. 2014;5:3545.

  20. Carter KA, Shao S, Hoopes MI, et al. Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nat Commun. 2014;5:3546.

  21. Di J, Kim J, Hu Q, Jiang X, Gu Z. Spatiotemporal drug delivery using laser-generated-focused ultrasound system. J Control Release. 2015;220:592-9.

  22. Oliveira H, Perez-Andres E, Thevenot J, Sandre O, Berra E, Lecommandoux S. Magnetic field triggered drug release from polymersomes for cancer therapeutics. J Control Release. 2013;169:165-70.

  23. Chakravarty R, Goel S, Cai W. Nanobody: the “magic bullet” for molecular imaging. Theranostics. 2014;4:386.

  24. Choi SW, Zhang Y, Xia Y. A temperature-sensitive drug release system based on phase-change materials. Angew Chem Int Ed Engl. 2010;49:7904-8.

  25. Sirivisoot S, Pareta R, Webster TJ. Electrically controlled drug release from nanostructured polypyrrole coated on titanium. Nanotechnology. 2011;22:085101.

  26. Wang Y, Zhou K, Huang G, et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat Mater. 2014;13:204-12.

  27. Sun CY, Shen S, Xu CF, et al. Tumor acidity-sensitive polymeric vector for active targeted siRNA delivery. J Am Chem Soc. 2015;137:15217-24.

  28. Cheng R, Meng F, Deng C, Zhong Z. Bioresponsive polymeric nanotherapeutics for targeted cancer chemotherapy. Nano Today. 2015; 10:656-70.

  29. Broaders KE, Grandhe S, Frechet JM. A biocompatible oxidation-triggered carrier polymer with potential in therapeutics. J Am Chem Soc. 2011;133:756-8.

  30. Wang M, Sun S, Neufeld CI, Perez-Ramirez B, Xu Q. Reactive oxygen species-responsive protein modification and its intracellular delivery for targeted cancer therapy. Angew Chem Int Ed Engl. 2014;53:13444-8.

  31. Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale. 2014;6:12273-86.

  32. Sun W, Jiang T, Lu Y, Reiff M, Mo R, Gu Z. Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J Am Chem Soc. 2014;136:14722-5.

  33. Mo R, Jiang T, Di J, Tai W, Gu Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev. 2014;43:3595-629.

  34. Zhang YQ, Yu JC, Shen QD, Gu Z. Glucose-responsive synthetic closedloop insulin delivery systems. Prog Chem. 2015;27:11-26.

  35. Hola K, Zhang Y, Wang Y, Giannelis EP, Zboril R, Rogach AL. Carbon dots—Emerging light emitters for bioimaging, cancer therapy and optoelectronics. Nano Today. 2014;9:590-603.

  36. Chen C, Peng J, Sun SR, Peng CW, Li Y, Pang DW. Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Nanomedicine (Lond). 2012;7:411-28.

  37. Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. Gold nanostructures: a class of multifunctional materials for biomedical applications. Chem Soc Rev. 2011;40:44-56.

  38. Furukawa H, Cordova KE, O’Keeffe M, Yaghi OM. The chemistry and applications of metal-organic frameworks. Science. 2013;341:1230444.

  39. Sun B, Sun MJ, Gu Z, et al. Conjugated polymer fluorescence probe for intracellular imaging of magnetic nanoparticles. Macromolecules. 2010;43:10348-54.

  40. Traina CA, Bakus RC, Bazan GC. Design and synthesis of monofunctionalized, water-soluble conjugated polymers for biosensing and imaging applications. J Am Chem Soc. 2011;133:12600-7.

  41. Ahmed E, Morton SW, Hammond PT, Swager TM. Fluorescent multiblock pi-conjugated polymer nanoparticles for in vivo tumor targeting. Adv Mater. 2013;25:4504-10.

  42. Yuan Y, Liu J, Liu B. Conjugated-polyelectrolyte-based polyprodrug: Targeted and image-guided photodynamic and chemotherapy with on-demand drug release upon Irradiation with a single light source. Angew Chem Int Ed Engl. 2014;126:7291-6.

  43. Jin GR, Mao D, Cai PQet al. Conjugated polymer nanodots as ultrastable long-term trackers to understand mesenchymal stem cell therapy in skin regeneration. Adv Funct Mater. 2015;25:4263-73.

  44. Pu KY, Shuhendler AJ, Jokerst JV, et al. Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice. Nat Nanotechnol. 2014;9:233-9.

  45. Zhang Z, Eyster TW, Ma PX. Nanostructured injectable cell microcarriers for tissue regeneration. Nanomedicine (Lond). 2016;11:1611-28.

  46. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine. 2008;3:133-49.

  47. Wu J, Kamaly N, Shi J, et al. Development of multinuclear polymeric nanoparticles as robust protein nanocarriers. Angew Chem Int Ed Engl. 2014;53:8975-9.

  48. Du AW, Stenzel MH. Drug carriers for the delivery of therapeutic peptides. Biomacromolecules. 2014;15:1097-114.

  49. Latorre A, Couleaud P, Aires A, Cortajarena AL, Somoza A. Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach. Eur J Med Chem. 2014;82:355-62.

  50. Culver H, Daily A, Khademhosseini A, Peppas N. Intelligent recognitive systems in nanomedicine. Curr Opin Chem Eng. 2014;4:105-13.

  51. Tang Y, Gan X, Cheheltani R, et al. Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model. Nanomedicine. 2014;10:1711-8.

  52. Howard M, Zern BJ, Anselmo AC, Shuvaev VV, Mitragotri S, Muzykantov V. Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano. 2014;8:4100-32.

  53. Gadde S, Even-Or O, Kamaly N, et al. Development of therapeutic polymeric nanoparticles for the resolution of inflammation. Adv Health Mater. 2014;3:1448-56.

  54. Marrache S, Pathnak RK, Darley KL, et al. Nanocarriers for tracking and treating diseases. Curr Med Chem. 2013;20:3500-14.

  55. Marrache S, Dhar S. Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc Natl Acad Sci USA. 2013;110: 9445-50.

  56. Jain KK. Nanobiotechnology and personalized medicine. Prog Mol Biol Transl Sci. 2011;104:325-54.

  57. Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract. 2008;17:89-101.

  58. Mulder WJ, Jaffer FA, Fayad ZA, Nahrendorf M. Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med. 2014;6:239sr1.

  59. Korin N, Kanapathipillai M, Matthews BD, et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science. 2010;337:738-42.

  60. Korin N, Gounis MJ, Wakhloo AK, Ingber DE. Targeted drug delivery to flow-obstructed vessels using mechanically activated nanotherapeutics. JAMA Neurol. 2015;72:119-22.

  61. Serpooshan V, Sivanesan S, Huang X, et al. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials. 2015;37:289-98.

  62. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52-79.

  63. Zins K, Sioud M, Aharinejad S, Lucas T, Abraham D. Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy. Methods Mol Biol. 2015;1218:143-61.

  64. Behzadi S, Serpooshan V, Sakhtianchi R, et al. Protein corona change the drug release profile of nanocarriers: the “overlooked” factor at the nanobio interface. Colloids Suf B Biointerfaces. 2014;123:143-9.

  65. Gu L, Faig A, Abdelhamid D, UHrich K. Sugar-based amphiphilic polymers for biomedical applications: from nanocarriers to therapeutics. Acc Chem Res. 2014;47:2867-77.

  66. Khalyfa A, Gozal D. Exosomal miRNAs as potential biomarkers of cardiovascular risk in children. J Transl Med. 2014;12:162.

  67. Bell IR, Ives JA, Jonas WB. Nonlinear effects of nanoparticles: biological variability from hermetic doses, small particle sizes, and dynamic adaptive interactions. Dose Response. 2013;12:202-32.

  68. Kransnoslobodtsev AV, Shlyakhtenko LS, Ukraintsev E, Zaikova TO, Keana JF, Lyubcchenko YL. Nanomedicine and protein misfolding diseases. Nanomedicine. 2005;1:300-5.

  69. Freitas RA. The future of nanofabrication and molecular scale devices in nanomedicine. Stud Health Technol Inform. 2002;80:45-59.

  70. Vélez JM, Vélez JJ. The eminent need for an academic program in universities to teach nanomedicine. Int J Nanomedicine. 2011;6:1733-8.

  71. Chiodo F, Marradi M, Calvo J, Yuste E, Penades S. Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein J Org Chem. 2014;10:1339-46.

  72. Blakney AK, Krogstad EA, Jiang YH, Woodrow KA. Delivery of multipurpose prevention drug combinations from Electrospun nanofibers using composite microarchitectures. Int J Nanomedicine. 2014;9:2967-78.

  73. Elsayed I, Abdelbary AA, Elshafeey AH. Nanosizing of a poorly soluble drug: technique optimization, factorial analysis, and pharmacokinetic study in healthy human volunteers. Int J Nanomedicine. 2014; 9:2943-53.

  74. Tintoré M, Eritja R, Fabrega C, DNA Nanoarchitectures: Steps towards biological applications. Chembiochem. 2014;15:1374-90.

  75. Zhao H, Li Y, Hu Y. Nanotechnologies in glycoproteomics. Clin Proteomics. 2014;11:21.

  76. Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics. 2014;4:175-200.




2020     |     www.medigraphic.com